Email this article 
Hide
Show all
Original Research
Molecular characterisation of rifampicin-resistant Mycobacterium tuberculosis strains from Malawi
Submitted: 08 April 2016 | Published: 31 March 2017
About the author(s)
Tarsizio Chikaonda, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa and UNC Project, Lilongwe, MalawiIrene Ketseoglou, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa
Nelson Nguluwe, UNC Project, Lilongwe, Malawi
Robert Krysiak, 2UNC Project, Lilongwe, Malawi
Isaac Thengolose, UNC Project, Lilongwe, Malawi
Felix Nyakwawa, Malawi National Tuberculosis Programme, Lilongwe, Malawi
Nora E. Rosenberg, UNC Project, Lilongwe, Malawi
Christopher Stanley, UNC Project, Lilongwe, Malawi
James Mpunga, Malawi National Tuberculosis Programme, Lilongwe, Malawi
Irving F. Hoffman, UNC Project, Lilongwe, Malawi and University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Maria A. Papathanasopoulos, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa
Mina Hosseinipour, UNC Project, Lilongwe, Malawi and University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Lesley Scott, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa
Wendy Stevens, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa
Abstract
Background: Availability and access to the detection of resistance to anti-tuberculosis drug sremains a significant challenge in Malawi due to limited diagnostic services. The Xpert® MTB/RIF can detect Mycobacterium tuberculosis and resistance to rifampicin in a single, rapid assay. Rifampicin-resistant M. tuberculosis has not been well studied in Malawi.
Objectives: We aimed to determine mutations in the rifampicin resistance determining region (RRDR) of the rpoB gene of M. tuberculosis strains which were defined as resistant to rifampicin by the Xpert MTB/RIF assay.
Methods: Rifampicin-resistant isolates from 43 adult patients (≥ 18 years) from various districts of Malawi were characterised for mutations in the RRDR (codons 507–533) of the rpoB gene by DNA sequencing.
Results: Mutations were found in 37/43 (86%) of the resistant isolates in codons 511, 512, 513,516, 522, 526 and 531. The most common mutations were in codons 526 (38%), 531 (29.7%) and 516 (16.2%). Mutations were not found in 6/43 (14%) of the resistant isolates. No novel rpoB mutations other than those previously described were found among the rifampicin-resistant M. tuberculosis complex strains.
Conclusion: This study is the first to characterise rifampicin resistance in Malawi. The chaintermination DNA sequencing employed in this study is a standard method for the determination of nucleotide sequences and can be used to confirm rifampicin resistance obtained using other assays, including the Xpert MTB/RIF. Further molecular cluster analysis, such as spoligotyping and DNA finger printing, is still required to determine transmission dynamics and the epidemiological link of the mutated strains.
Keywords
Metrics
Total abstract views: 4200Total article views: 6716
Crossref Citations
1. Distribución y frecuencia de potenciales mutaciones asociadas con la resistencia a rifampicina en el gen rpoB de Mycobacterium tuberculosis detectadas mediante un método molecular automatizado
Adrian Peñata, Camilo Pérez, Tatiana Castaño, Julián Bustamante, Sigifredo Ospina
Revista de la Facultad de Medicina vol: 71 issue: 1 first page: e98079 year: 2022
doi: 10.15446/revfacmed.v71n1.98079